» Articles » PMID: 38592034

Timing of Moderate to Vigorous Physical Activity, Mortality, Cardiovascular Disease, and Microvascular Disease in Adults With Obesity

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2024 Apr 9
PMID 38592034
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the association between timing of aerobic moderate to vigorous physical activity (MVPA) and risk of cardiovascular disease (CVD), microvascular disease (MVD), and all-cause mortality in adults with obesity and a subset with obesity and type 2 diabetes (T2D).

Research Design And Methods: Participants included adults with obesity (BMI ≥30 kg/m2) and a subset of those with T2D from the UK Biobank accelerometry substudy. Aerobic MVPA was defined as bouts of MVPA lasting ≥3 continuous minutes. Participants were categorized into morning, afternoon, or evening MVPA based on when they undertook the majority of their aerobic MVPA. The reference group included participants with an average of less than one aerobic MVPA bout per day. Analyses were adjusted for established and potential confounders.

Results: The core sample included 29,836 adults with obesity, with a mean age of 62.2 (SD 7.7) years. Over a mean follow-up period of 7.9 (SD 0.8) years, 1,425 deaths, 3,980 CVD events, and 2,162 MVD events occurred. Compared with activity in the reference group, evening MVPA was associated with the lowest risk of mortality (hazard ratio [HR] 0.39; 95% CI 0.27, 0.55), whereas afternoon (HR 0.60; 95% CI 0.51, 0.71) and morning MVPA (HR 0.67; 95% CI 0.56, 0.79) demonstrated significant but weaker associations. Similar patterns were observed for CVD and MVD incidence, with evening MVPA associated with the lowest risk of CVD (HR 0.64; 95% CI 0.54, 0.75) and MVD (HR 0.76; 95% CI 0.63, 0.92). Findings were similar in the T2D subset (n = 2,995).

Conclusions: Aerobic MVPA bouts undertaken in the evening were associated with the lowest risk of mortality, CVD, and MVD. Timing of physical activity may play a role in the future of obesity and T2D management.

Citing Articles

Physical activity and metabolic health: Is it all in the timing?.

Henson J, Davies M, Hall A, Yates T Int J Obes (Lond). 2025; .

PMID: 40087505 DOI: 10.1038/s41366-025-01736-2.


Physical activity, cardiovascular disease, and mortality across obesity levels.

Tian Q, Chen S, Liu S, Li Y, Wu S, Wang Y EPMA J. 2025; 16(1):51-65.

PMID: 39991104 PMC: 11842671. DOI: 10.1007/s13167-025-00397-5.


Association of oxidative balance score with all-cause and cardiovascular mortality in overweight and obese.

Ying S, Ding H, Chen Y, Zheng S Front Nutr. 2025; 12:1536024.

PMID: 39935578 PMC: 11810733. DOI: 10.3389/fnut.2025.1536024.


Diurnal timing of physical activity in relation to obesity and diabetes in the German National Cohort (NAKO).

Stein M, Weber A, Bamberg F, Baurecht H, Berger K, Bohmann P Int J Obes (Lond). 2025; .

PMID: 39856244 DOI: 10.1038/s41366-025-01721-9.


Moderate-to-vigorous physical activity does not improve mortality in type 2 diabetes patients with severe abdominal aortic calcification.

Sheng C, Xiong Y, Yang P, Wang W PLoS One. 2025; 20(1):e0317007.

PMID: 39787148 PMC: 11717319. DOI: 10.1371/journal.pone.0317007.


References
1.
Kanaley J, Colberg S, Corcoran M, Malin S, Rodriguez N, Crespo C . Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine. Med Sci Sports Exerc. 2022; 54(2):353-368. PMC: 8802999. DOI: 10.1249/MSS.0000000000002800. View

2.
Beltran-Valls M, Cabanas-Sanchez V, Sadarangani K, Rodriguez-Artalejo F, Moliner-Urdiales D, Martinez-Gomez D . Physical activity and diabetes mortality in people with type 2 diabetes: a prospective cohort study of 0.5 million US people. Diabetes Metab. 2022; 49(1):101410. DOI: 10.1016/j.diabet.2022.101410. View

3.
Hargreaves M, Spriet L . Skeletal muscle energy metabolism during exercise. Nat Metab. 2020; 2(9):817-828. DOI: 10.1038/s42255-020-0251-4. View

4.
Garg S, Kushwaha K, Dubey R, Gupta J . Association between obesity, inflammation and insulin resistance: Insights into signaling pathways and therapeutic interventions. Diabetes Res Clin Pract. 2023; 200:110691. DOI: 10.1016/j.diabres.2023.110691. View

5.
Mason I, Qian J, Adler G, Scheer F . Impact of circadian disruption on glucose metabolism: implications for type 2 diabetes. Diabetologia. 2020; 63(3):462-472. PMC: 7002226. DOI: 10.1007/s00125-019-05059-6. View